Skip to main content
. 2019 Nov 29;7:333. doi: 10.1186/s40425-019-0824-5

Fig. 3.

Fig. 3

Potential combination therapies according to the immune profiles of hepatocellular carcinoma (HCC). CTLA4: cytotoxic T lymphocyte antigen-4; PD-1: programmed cell death-1; TILs: tumor-infiltrating lymphocytes; TAM: tumor-associated macrophage; TGF-β: Transforming growth factor β